https://orcid.org/0000-0001-5064-7206
References
- Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases. Blood. 2008;111(2):838–845.
- Michonneau D, Petrella T, Ortonne N, et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017;97(3):358–364.
- Setiadi A, Zoref-Lorenz A, Lee CY, et al. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022;9(3):e217–e227.
- Gayden T, Sepulveda FE, Khuong-Quang DA, et al. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet. 2018;50(12):1650–1657.
- Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol. 2021;106(5):654–661.
- Levy R, Fusaro M, Guerin F, et al. Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4(7):1383–1387.
- Lin TA, Yang CF, Liu YC, et al. Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population. Int J Hematol. 2019;109(2):187–196.
- Izumi K, Kanda J, Nishikori M, et al. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto stem cell transplantation group. Ann Hematol. 2019;98(12):2815–2823.
- Jothishankar B, Espinosa ML, Zain J, et al. Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma. JAAD Case Rep. 2020;6(12):1245–1247.
- Li L, Wu C, Chai Y, et al. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: an unusual case report and literature review. Int J Immunopathol Pharmacol. 2021;35:20587384211009342.
- Ware O, Tarabadkar ES, Shustov A, et al. Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome. J Am Acad Dermatol. 2020;82(2):489–491.
- Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–1822.
- La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477.
- Elli EM, Barate C, Mendicino F, et al. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019;9:1186.
- Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210–e212.
- Tvorogov D, Thomas D, Liau NPD, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Sci Adv. 2018;4(11):eaat3834.
- Zhang Q, Wei A, Ma HH, et al. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. Haematologica. 2021;106(7):1892–1901.
- Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828–2837.